Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 30, 2027

Conditions

Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

Venetoclax

VENETOCLAX: Ramp-up than 400 mg QD

DRUG

Rituximab

RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2

DRUG

Ibrutinib

IBRUTINIB 420 mg QD

Trial Locations (1)

RECRUITING

IRCCS Ospedale San Raffaele, Milan

All Listed Sponsors

lead

Paolo Ghia

OTHER